The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Alpha2-adrenergic agonists for the management of opioid withdrawal
Open accessAbstract
BACKGROUND: Withdrawal is a necessary step prior to drug-free treatment or as the endpoint of long-term substitution treatment. OBJECTIVES: To assess the effectiveness of interventions involving the use of alpha2-adrenergic agonists compared with placebo, reducing doses of methadone, symptomatic medications, or an alpha2-adrenergic agonist regimen different to the experimental intervention, for the management of the acute phase of opioid withdrawal. Outcomes included the withdrawal syndrome experienced, duration of treatment, occurrence of adverse effects, and completion of treatment. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (1946 to November week 2, 2015), EMBASE (January 1985 to November week 2, 2015), PsycINFO (1806 to November week 2, 2015), Web of Science, and reference lists of articles. SELECTION CRITERIA: Randomised controlled trials comparing alpha2-adrenergic agonists (clonidine, lofexidine, guanfacine, tizanidine) with reducing doses of methadone, symptomatic medications or placebo, or comparing different alpha2-adrenergic agonists to modify the signs and symptoms of withdrawal in participants who were opioid dependent. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by The Cochrane Collaboration. MAIN RESULTS: We included 26 randomised controlled trials involving 1728 participants. Six studies compared an alpha2-adrenergic agonist with placebo, 12 with reducing doses of methadone, four with symptomatic medications, and five compared different alpha2-adrenergic agonists. We assessed 10 studies as having a high risk of bias in at least one of the methodological domains that were considered.We found moderate-quality evidence that alpha2-adrenergic agonists were more effective than placebo in ameliorating withdrawal in terms of the likelihood of severe withdrawal (risk ratio (RR) 0.32, 95% confidence interval (CI) 0.18 to 0.57; 3 studies; 148 participants). We found moderate-quality evidence that completion of treatment was significantly more likely with alpha2-adrenergic agonists compared with placebo (RR 1.95, 95% CI 1.34 to 2.84; 3 studies; 148 participants).Peak withdrawal severity may be greater with alpha2-adrenergic agonists than with reducing doses of methadone, as measured by the likelihood of severe withdrawal (RR 1.18, 95% CI 0.81 to 1.73; 5 studies; 340 participants; low quality), and peak withdrawal score (standardised mean difference (SMD) 0.22, 95% CI -0.02 to 0.46; 2 studies; 263 participants; moderate quality), but these differences were not significant and there is no significant difference in severity when considered over the entire duration of the withdrawal episode (SMD 0.13, 95% CI -0.24 to 0.49; 3 studies; 119 participants; moderate quality). The signs and symptoms of withdrawal occurred and resolved earlier with alpha2-adrenergic agonists. The duration of treatment was significantly longer with reducing doses of methadone (SMD -1.07, 95% CI -1.31 to -0.83; 3 studies; 310 participants; low quality). Hypotensive or other adverse effects were significantly more likely with alpha2-adrenergic agonists (RR 1.92, 95% CI 1.19 to 3.10; 6 studies; 464 participants; low quality), but there was no significant difference in rates of completion of withdrawal treatment (RR 0.85, 95% CI 0.69 to 1.05; 9 studies; 659 participants; low quality).There were insufficient data for quantitative comparison of different alpha2-adrenergic agonists. Available data suggest that lofexidine does not reduce blood pressure to the same extent as clonidine, but is otherwise similar to clonidine. AUTHORS' CONCLUSIONS: Clonidine and lofexidine are more effective than placebo for the management of withdrawal from heroin or methadone. We detected no significant difference in efficacy between treatment regimens based on clonidine or lofexidine and those based on reducing doses of methadone over a period of around 10 days, but methadone was associated with fewer adverse effects than clonidine, and lofexidine has a better safety profile than clonidine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Clonidine blocks acute opiate-withdrawal symptoms
Gold, M., Redmond, D. E., & Kleber, H. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92823-4 · Cited by 710
THALIDOMIDE AND LIMB DEFORMITIES
Millen, J. (1962) · The Lancet · doi:10.1016/s0140-6736(62)90462-2 · Cited by 462
Global statistics on addictive behaviours: 2014 status report
Gowing, L. R., Ali, R. L., Allsop, S., Marsden, J., Turf, E. E., West, R., & Witton, J. (2015) · Addiction · doi:10.1111/add.12899 · Cited by 410
Self-citationOpiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment
Gold, M. S. (1980) · JAMA · doi:10.1001/jama.243.4.343 · Cited by 326
What Can Long‐term Follow‐up Teach us About Relapse and Prevention of Relapse in Addiction?
VAILLANT, G. E. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb03021.x · Cited by 315
Buprenorphine for the management of opioid withdrawal
Gowing, L., Ali, R., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002025.pub4 · Cited by 297
Self-citationThe economic costs of heroin addiction in the United States
Mark, T. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00162-9 · Cited by 271
Lapse, Relapse and Survival among Opiate Addicts after Treatment: A Prospective Follow-up Study
Gossop, M., Green, L., Phillips, G., & Bradley, B. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.3.348 · Cited by 230
SERUM-SICKNESS-LIKE SYNDROME WITH MEMBRANOUS GLOMERULOPATHY IN PATIENT ON CAPTOPRIL
Hoorntje, S., Weening, J., Kallenberg, C. M., Prins, E. L., & Donker, A. M. (1979) · The Lancet · doi:10.1016/s0140-6736(79)92303-1 · Cited by 225
Methadone at tapered doses for the management of opioid withdrawal
Amato, L., Davoli, M., Minozzi, S., Ferroni, E., Ali, R., & Ferri, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003409.pub4 · Cited by 222
Self-citationAmato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005031.pub4 · Cited by 221
Principles of addiction medicine
Ries, R. R., Fiellin, D. A., Miller, S. C., & Saitz, R. (2009) · Cited by 218
Are detoxification programmes effective?
Mattick, R. P., & Hall, W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90215-9 · Cited by 196
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.1.100 · Cited by 189
Three Methods of Opioid Detoxification in a Primary Care Setting: A Randomized Trial
O'Connor, P. G., Carroll, K. M., Shi, J. M., Schottenfeld, R. S., Kosten, T. R., & Rounsaville, B. J. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-7-199710010-00004 · Cited by 178
Clonidine in Morphine Withdrawal: Differential Effects on Signs and Symptoms
Jasinski, D. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790340041006 · Cited by 163
Should protracted withdrawal from drugs be included in DSM-IV?
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.695 · Cited by 158
Charney, D. S., Sternberg, D. E., Kleber, H. D., Heninger, G. R., & Redmond, D. E. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780360089010 · Cited by 155
Clonidine and the treatment of the opiate withdrawal syndrome
Gossop, M. (1988) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(88)90078-6 · Cited by 131
Trends in opiate overdose deaths in Australia 1979–1995
Hall, W., & Darke, S. G. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00044-1 · Cited by 130
Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months
Broers, B., Giner, F., Dumont, P., & Mino, A. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00063-0 · Cited by 128
Clonidine in Outpatient Detoxification From Methadone Maintenance
Kleber, H. D. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790270081009 · Cited by 127
A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids
Cheskin, L. J., Fudala, P. J., & Johnson, R. E. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90093-0 · Cited by 121
Clonidine for opiate detoxification: outpatient clinical trials
Washton, A. M., & Resnick, R. B. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.9.1121 · Cited by 117
Farrell, M. (1994) · Addiction · doi:10.1111/j.1360-0443.1994.tb03745.x · Cited by 116
Self-citationThe Influence of Psychological Factors on the Opiate Withdrawal Syndrome
Phillips, G., Gossop, M., & Bradley, B. P. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.149.2.235 · Cited by 110
Does post‐withdrawal cue exposure improve outcome in opiate addiction? A controlled trial
Dawe, S., Powell, J. E., Richards, D. A., Gossop, M., Marks, I. M., Strang, J., & Gray, J. A. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02146.x · Cited by 103
Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital
Kahn, A., Mumford, J. P., Rogers, G. A., & Beckford, H. (1997) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(96)01316-6 · Cited by 98
Bearn, J., Gossop, M., & Strang, J. (1996) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(96)01289-6 · Cited by 95
Clonidine and opiate receptor antagonists in the treatment of heroin addiction
Gerra, G., Marcato, A., Caccavari, R., Fontanesi, B., Delsignore, R., Affini, G. F., Avanzini, P., Rustichelli, P., & Passeri, M. (1995) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(94)00077-8 · Cited by 90
Buprenorphine in opiate withdrawal: A comparison with clonidine
NIGAM, A. K., Ray, R., & Tripathi, B. M. (1993) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(93)90024-v · Cited by 90
Interaction of EEG sleep, antidepressants, and affective disease.
Hd, K., & Riordan, C. E. (1982) · PubMed · Cited by 85
Lin, S., Strang, J., Su, L., Tsai, C., & Hu, W.-H. (1997) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(97)00116-6 · Cited by 84
Akhondzadeh, S., Ahmadi-Abhari, S. A., Assadi, S. M., Shabestari, O. L., Kashani, A. R., & Farzanehgan, Z. M. (2000) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2000.00295.x · Cited by 84
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal
Gowing, L., Ali, R. L., & White, J. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002022.pub3 · Cited by 84
Self-citationCarnwath, T., & Hardman, J.-A. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00040-4 · Cited by 82
Opioid antagonists with minimal sedation for opioid withdrawal
Gowing, L., Ali, R. L., & White, J. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002021.pub4 · Cited by 78
Self-citationPrimary care-based ambulatory opioid detoxification
O’Connor, P. G., Waugh, M. E., Carroll, K. M., Rounsaville, B. J., Diagkogiannis, I. A., & Schottenfeld, R. S. (1995) · Journal of General Internal Medicine · doi:10.1007/bf02599882 · Cited by 78
Janiri, L., Mannelli, P., Persico, A. M., Serretti, A., & Tempesta, E. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90096-5 · Cited by 75
Yu, E., Miotto, K. A., Akerele, E., MONTGOMERY, A., Elkashef, A. M., Walsh, R., Montoya, I. D., Fischman, M. W., Collins, J., McSherry, F., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.04.002 · Cited by 71
Use of qigong therapy in the detoxification of heroin addicts.
Li, M., Chen, K. M., & Mo, Z. (2002) · PubMed · Cited by 68
Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. (1985) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952998509016845 · Cited by 66
Efficacy of clonidine and of methadone in the rapid detoxification of patients dependent on heroin
Camí, J., de Torres, S., San, L., Solé, À., Guerra, D., & Ugena, B. (1985) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1985.182 · Cited by 65
Bearn, J., Gossop, M., & Strang, J. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00030-1 · Cited by 63
Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005031.pub2 · Cited by 62
Amato, L., Minozzi, S., Davoli, M., Vecchi, S., Ferri, M., & Mayet, S. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005031 · Cited by 61
DETOXIFICATION FROM HEROIN DEPENDENCY: AN OVERVIEW OF METHOD AND EFFECTIVENESS
Lipton, D. S., & Maranda, M. J. (1982) · Advances in Alcohol & Substance Abuse · doi:10.1300/j251v02n01_03 · Cited by 60
Umbricht, A., Hoover, D. R., TUCKER, M., Leslie, J. M., Chaisson, R. E., & Preston, K. L. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00325-3 · Cited by 59
SAN, L., Camí, J., PERI, J. M., MATA, R., & Porta, M. S. (1990) · British Journal of Addiction · doi:10.1111/j.1360-0443.1990.tb00634.x · Cited by 58
Outpatient versus inpatient opioid detoxification: A randomized controlled trial
Day, E., & Strang, J. (2010) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.007 · Cited by 58
Lofexidine versus clonidine in rapid opiate detoxification
Gerra, G., Zaimovic, A., Giusti, F., Gennaro, C. D., Zambelli, U., Gardini, S., & Delsignore, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00178-7 · Cited by 57
BESWICK, T., Best, D. W., REES, S., Bearn, J., Gossop, M., & Strang, J. (2003) · Addiction Biology · doi:10.1080/1355621031000069882 · Cited by 56
Hypercortisolism after opioid discontinuation in rapid detoxification of heroin addicts
CAMÍ, J., GILABERT, M., SAN, L., & DE LA TORRE, R. (1992) · British Journal of Addiction · doi:10.1111/j.1360-0443.1992.tb02001.x · Cited by 55
Opiate Detoxification Protocols: A Clinical Manual
Fishbain, D. A., Rosomoff, H. L., Cutler, R., & Rosomoff, R. S. (1993) · Annals of Clinical Psychiatry · doi:10.3109/10401239309148924 · Cited by 53
Inpatient versus other settings for detoxification for opioid dependence
Day, E., Ison, J., & Strang, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004580.pub2 · Cited by 48
Success and Failure at Inpatient Heroin Detoxification
SAN, L., Camí, J., PERI, J. M., MATA, R., & Porta, M. S. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00554.x · Cited by 44
Rapid opiate detoxication in outpatient treatment
Gerra, G., Zaimovic, A., Rustichelli, P., Fontanesi, B., Zambelli, U., Timpano, M., Bocchi, C., & Delsignore, R. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00050-1 · Cited by 43
Ahmadi-Abhari, S. A., Akhondzadeh, S., Assadi, S. M., Shabestari, O. L., Farzanehgan, Z. M., & Kamlipour, A. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00325.x · Cited by 43
Pharmacological therapies for management of opium withdrawal
Rahimi‐Movaghar, A., Gholami, J., Amato, L., Hosseini, L. J., Nooraie, R. Y., & Amin‐Esmaeili, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007522.pub2 · Cited by 39
Type of hospital setting and treatment outcome with heroin addicts: Results from a randomised trial
Strang, J., Marks, I. M., Dawe, S., Powell, J. E., Gossop, M., Richards, D. A., & Gray, J. A. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.4.335 · Cited by 38
Detoxification treatments for opiate dependent adolescents
Minozzi, S., Amato, L., Bellisario, C., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006749.pub3 · Cited by 37
Pharmacological Advances in Addiction Treatment
Preston, K. L., & Bigelow, G. E. (1985) · International Journal of the Addictions · doi:10.3109/10826088509047756 · Cited by 37
White, R., Alcorn, R., & Feinmann, C. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00149-1 · Cited by 36
Gold, M. S., Pottash, A. L. C., Sweeney, D. R., Davies, R. K., & Hd, K. (1980) · PubMed · Cited by 35
Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts
Dawe, S., & Gray, J. A. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01159-8 · Cited by 34
WALSH, S. L., Strain, E. C., & Bigelow, G. E. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00372.x · Cited by 32
McCambridge, J., Gossop, M., Beswick, T., Best, D. W., Bearn, J., Rees, S., & Strang, J. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.09.020 · Cited by 30
Opioid antagonists with minimal sedation for opioid withdrawal
Gowing, L., Ali, R. L., & White, J. M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002021.pub3 · Cited by 27
Self-citationKasvikis, Y., Bradley, B. P., Gossop, M., Griffiths, P., & Marks, I. M. (1990) · International Journal of the Addictions · doi:10.3109/10826089009058878 · Cited by 23
Beswick, T., Best, D. W., Bearn, J., Gossop, M., Rees, S., & Strang, J. (2003) · American Journal on Addictions · doi:10.1111/j.1521-0391.2003.tb00544.x · Cited by 20
The detoxification of high dose heroin addicts in Pakistan
Gossop, M. (1989) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(89)90077-x · Cited by 18
Audit of the in-patient management of opioid withdrawal using lofexidine hydrochloride
Sheridan, J. L., Cook, C. C. H., & Strang, J. (1999) · Journal of Substance Use · doi:10.3109/14659899909052892 · Cited by 17
Clinical utility of clonidine in opiate withdrawal: a study of 100 patients.
Gold, M. S., & Hd, K. (1981) · PubMed · Cited by 17
San, L., Fernandez, T., Camí, J., & Gossop, M. (1994) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(94)90100-7 · Cited by 16
A Nonopioid Procedure for Outpatient Opioid Detoxification
Ockert, D. M., Volpicelli, J. R., Baier, A. R., Coons, E. E., & Fingesten, A. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3181e518cc · Cited by 15
Relationship of depression to clonidine detoxification of opiate addicts
Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. (1984) · Comprehensive Psychiatry · doi:10.1016/0010-440x(84)90049-x · Cited by 15
Lin, S., Pan, C., & Chen, C. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000144 · Cited by 15
Muga, R., Tor, J., Forteza-Rei, J., et al. (1990) · PubMed · Cited by 5
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
The Neuroscience of Drug Reward and Addiction
Volkow, N. D., Michaelides, M., & Baler, R. (2019) · Physiological Reviews · doi:10.1152/physrev.00014.2018 · Cited by 863
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making
Naqvi, N. H., & Bechara, A. (2010) · Brain Structure and Function · doi:10.1007/s00429-010-0268-7 · Cited by 598
Treatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
Metadata
- Authors
- Gowing, L., Farrell, M., Ali, R., & White, J. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-03
- Volume
- 2016
- Issue
- 5
- Pages
- CD002024-CD002024
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2135387265
- Cited by
- 271
- References
- 80
- FWCI
- 23.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.